CCM
PRCT icon

Coldstream Capital Management’s Procept Biorobotics PRCT Stock Holding History

Coldstream Capital Management’s Portfolio PRCT Stock Details PRCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-368
Closed -$21.4K – 2759
2025
Q1 		$21.4K Buy
+368
New +$25.1K ﹤0.01% 2084

Other funds holding PRCT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Coldstream Capital Management's PRCT Position: Q2 2025 in Review

Coldstream Capital Management sold out of Procept Biorobotics (PRCT) in Q2 2025, closing a stake of 368 shares — an estimated $21.4K sold.

Coldstream Capital Management first reported a position in PRCT in Q1 2025 and held it in 1 quarter. The position peaked at $21.4K in Q1 2025. 271 funds tracked by Wall St. Rank hold PRCT as of Q2 2025.

  • Coldstream Capital Management reported no remaining Procept Biorobotics position as of Q2 2025 after selling out during the quarter.
  • Coldstream Capital Management sold 368 Procept Biorobotics shares in Q2 2025, an estimated $21.4K.
  • Coldstream Capital Management first reported a position in Procept Biorobotics in Q1 2025 and held it in 1 quarter.
  • Coldstream Capital Management's Procept Biorobotics position peaked at $21.4K in Q1 2025.
  • 271 funds tracked by Wall St. Rank held Procept Biorobotics as of Q2 2025.

Based on Coldstream Capital Management's 13F filing for Q2 2025, filed 12 Aug 2025.